Kimberly A. Yonkers, M.D.
Name, Degree: Kimberly A. Yonkers, M.D.
Role(s) in Task Force and Work Group: Member, DSM-V Task Force
Institutional Affiliation(s): Yale School of Medicine
City, State: New Haven, CT
Biographical Sketch:
Dr. Yonkers is an Associate Professor at the Yale School of Medicine where she directs the PMS and Perinatal Depression Research Program. She holds appointments in the Departments of Psychiatry (Primary), Obstetrics, Gynecology and Reproductive Sciences, and in the School of Epidemiology and Public Health. She has longstanding interests in the clinical course, biological underpinnings and treatment of mood and anxiety disorders as they occur in women. This has included investigations into sex differences in illness expression and treatment and the identification, treatment and causes of disorders only occurring in women, such as premenstrual dysphoric disorder. A related interest has been the care of women who suffer from psychiatric illness during pregnancy and the postpartum period. She has been actively exploring behavioral treatments that may help pregnant women decrease or stop using hazardous substance use. She is also currently researching the possible impact of depressive disorders, or their treatment, on perinatal outcomes.
Uncompensated affiliations with non-profit or advocacy organizations that may have a direct or indirect interest in psychiatric diagnosis, treatment, or the DSM-V : Three calendar years before nomination and Each year thereafter through the present calendar year. (For 2008, activities to date and commitments for remainder of year.)
|
Non-Profit and Advocacy Organizations |
Year(s) |
Role |
|
International Association for Women’s Mental Health |
2004-2008 |
Secretary |
|
North American Society for Psychosocial Obstetrics and Gynecology |
2005-2007
2007-2009 |
Treasurer
President |
The two tables below represent Dr. Yonkers’ disclosure of significant interests and affiliations for: (1) The time period including the 3 years prior to nomination to serve on the DSM-V Task Force; the calendar year in which nomination to the Task Force occurred; through the calendar year in which the nomination was approved; and (2) the time period including the calendar year after approval, and each successive year to the present.
Dr. Yonkers has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, her aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed $10,000 in any calendar year.
|
KEY NUMBER:
1. Consultation Fees (include scientific advisory boards)
2. Full- or Part-time Employee
3. Industry-related Grant-Research Support received or pending
4. Honoraria (includes Speakers’ Bureau)
5. Stock or other financial options |
6. Expert testimony
7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)
8. Patents received or pending
9. Officer, director/trustee, executive (specify)
10. Other (specify) |
Disclosure of significant interests including: Three (3) calendar years before nomination, the calendar year of nomination, through the calendar year of approval to serve on the DSM-V Task Force
|
Commercial or Other Organization |
Year(s) |
Key #(s) |
|
Pfizer |
2003
2004
2005 |
1,4,10*
10*
10* |
|
Berlex |
2003
2004
2005
2006 |
3
1,3,4
1,4
1,4 |
|
Wyeth
|
2003
2004
2005
2006 |
1,4
1,4
1,4
1,3,4 |
|
GSK |
2003
2004
2005 |
1,3,4
1,3,4
3 |
|
Warner Chilcott |
2003 |
1 |
|
NARSAD |
2006 |
3 (Foundation) |
|
Shering-AG (through WPA) |
2005 |
1 |
*Medication for an NIMH trial
Disclosure of significant interests Beginning with the calendar year after APA Board of Trustees approval to serve on the DSM-V Task Force, to the present. (For 2008, activities to date and commitments for remainder of year.) (Since AUGUST 2006)
|
Commercial or Other Organization |
Year(s) |
Key #(s) |
|
Berlex |
2007 |
4 |
|
Wyeth |
2007 |
3,4 |
|
Pfizer |
2007
2008 |
10
10 |
|
Eli Lilly |
2007
2008 |
3
3 |
|
NARSAD |
2007
2008 |
3 (Foundation)
3 (Foundation) |